// Biotech and Pharma Therapeutics
Will private insurers follow Medicare to digital cognitive screenings?
November 19, 2025 / Digital cognitive screening / Brain health AI / Early dementia detection / Medicare brain screening / Cognitive decline prevention
AI-based digital cognitive screenings show promise for early detection of cognitive decline, with Medicare support already in place. Experts predict private insurers will follow by 2026, recognizing both clinical and economic benefits of proactive brain health assessment starting at age 55.
Overcoming AI Medical Device Reimbursement Woes
November 19, 2025 / AI medical devices / Medicare CPT codes / Digital health reimbursement / AI cancer mapping / FDA CMS pathways
AI-driven medical devices face significant reimbursement challenges, despite FDA approval. Avenda Health’s Unfold AI overcame these by securing a new CPT code and Medicare payment rate, showing the importance of early engagement with regulatory and payer stakeholders in digital health innovation.
Dexcom’s Smart Basal Clearance Is a Bright Spot in Tough 2025
November 19, 2025 / CGM insulin titration / Dexcom Smart Basal / Type 2 diabetes / Basal insulin optimizer / FDA diabetes tools
Dexcom’s FDA-cleared Smart Basal tool uses CGM data to personalize basal insulin dosing for adults with Type 2 diabetes on glargine U-100. It aims to improve titration accuracy, adherence, and reduce clinical workload despite recent technical and operational setbacks.
Providence, University of Montana team up to tackle rural health crisis
November 18, 2025 / rural health initiative / healthcare access Montana / Providence partnership / rural care models / University of Montana
Providence and the University of Montana have launched a collaborative initiative to address rural healthcare disparities by designing tailored care strategies, aiming to improve access, outcomes, and sustainability for rural providers and patients through a unified operational framework.
GSK pens $50M LTZ pact to join Big Pharma peers in emerging myeloid cell engager space
November 19, 2025 / GSK / myeloid cell engagers / cancer immunotherapy / LTZ partnership / bispecific antibody therapy / hematologic cancer / solid tumor treatment
GSK partnered with LTZ Therapeutics in a $50M deal to develop first-in-class myeloid cell engagers targeting hematologic cancers and solid tumors, expanding its oncology pipeline into an emerging immunotherapy space attracting major pharmaceutical players like Sanofi and Pfizer.
// 4th Industrial Revolution
Philips, Edwards team on AI-based guide for mitral valve repair
November 19, 2025 / AI navigation / mitral valve repair / TEER procedure / Philips Edwards / real-time guidance / cardiac imaging / DeviceGuide system
Philips and Edwards Lifesciences have developed DeviceGuide, an AI-powered navigation tool that provides real-time guidance during mitral valve TEER procedures, enhancing clinical decision-making. It’s currently in limited release in Europe and under FDA review for U.S. approval.
Millie Introduces AI Solution for Maternity Care
November 19, 2025 / AI maternity care / personalized pregnancy support / maternal health crisis
Millie launched Maia, an AI-driven tool for maternity care that provides personalized support, appointment management, and real-time clinical escalation. Integrated into Millie’s app, Maia addresses gaps in prenatal and postpartum care amid the U.S. maternal health crisis.
Philips and Cortechs.ai Expand Partnership to Embed AI Neuroimaging Analytics in MR System
November 19, 2025 / AI neuroimaging integration / Alzheimer’s MRI diagnostics / MS brain analysis
Philips and Cortechs.ai are integrating AI-powered neuroimaging tools directly into Philips MR systems, enabling automated, quantitative analysis for conditions like Alzheimer’s and MS. This streamlines diagnostics, reduces variability, and improves workflow efficiency amid rising neuroimaging demand and staffing shortages.
TE Connectivity Expands Medical Device Rapid Prototyping Capabilities into U.S.
November 19, 2025 / medical prototyping USA / surgical robotics innovation / rapid device development
TE Connectivity has expanded its Propelus rapid prototyping centers to the U.S., offering advanced engineering support for faster development of medical devices like catheters and surgical robotics, enhancing collaboration and accelerating innovation in cardiovascular and interventional technologies.
Oral microsphere pills can detect markers of gastrointestinal disease
November 19, 2025 / gastrointestinal disease detection / noninvasive colon cancer test / ingestible biosensor pills
Researchers have developed ingestible microsphere pills containing blood-sensing bacteria to detect gastrointestinal disease markers noninvasively. In mouse models, the pills rapidly identified intestinal bleeding, offering a promising alternative to invasive colonoscopies for detecting conditions like colitis and colorectal cancer.
// Business & Markets
Humana and Epic Launch Coverage Finder to Deliver Digital-First Medicare Advantage Check-In
November 18, 2025 / Medicare Advantage automation / digital insurance verification / Epic Coverage Finder
Humana and Epic have launched a digital Coverage Finder and Insurance Card Exchange for Medicare Advantage members, automating insurance verification at check-in. This improves billing accuracy, reduces paperwork, and supports CMS’s goal of a modern, patient-centered healthcare infrastructure.
Exact Sciences Catapults, Breaking Out, On Rumored Abbott Laboratories Buyout
November 19, 2025 / Exact Sciences acquisition / Abbott Laboratories buyout / cancer diagnostics deal
Exact Sciences surged 23.7% amid rumors of a potential acquisition by Abbott Laboratories. The deal would expand Abbott’s oncology portfolio with Exact’s cancer detection technologies, signaling a strategic move into broader cancer diagnostics and screening capabilities.
Lilly’s Weight Loss Trio Could Top $100B in Revenue Thanks to Oral Option
November 19, 2025 / Lilly obesity drugs / orforglipron weight loss / Medicare access expansion
Eli Lilly’s obesity drug portfolio, including oral orforglipron, could exceed $100B in global revenue. Analysts project rapid uptake driven by favorable pricing, broader Medicare access, and patient preference for oral therapies in treating obesity and type 2 diabetes.
Novartis to build manufacturing hub in North Carolina, creating 700 jobs
November 19, 2025 / Novartis / pharmaceutical manufacturing / biologics expansion / North Carolina / drug production / job creation
Novartis will invest in a major North Carolina manufacturing hub to increase U.S. production of key medicines, supporting biologics, sterile packaging, and solid dosage forms, while creating 700 direct and 3,000 indirect jobs by 2030.
Arbiter Emerges from Stealth with $52M Funding to End Healthcare Fragmentation with AI
November 19, 2025 / AI healthcare / care coordination / patient outcomes / Arbiter platform / healthcare fragmentation / payer-provider alignment
Arbiter has launched from stealth with $52M to combat healthcare fragmentation using AI. Its platform unites payers, providers, and patients by automating care coordination, optimizing site-of-care decisions, and streamlining referrals, authorizations, and scheduling through an integrated Record-Action-Alignment model.
// Legal & Regulatory
Bayer Lung Cancer Drug Lands Speedy FDA Nod to Stay Competitive With a Boehringer Ingelheim Med
November 19, 2025 / HER2 lung cancer / Bayer Hyrnuo FDA / targeted cancer therapy / non-small cell / accelerated drug approval / oncology treatment
The FDA granted accelerated approval to Bayer’s Hyrnuo for advanced HER2-mutant non-small cell lung cancer, offering a new targeted therapy option. The drug enters direct competition with Boehringer Ingelheim’s recently approved HER2-targeting treatment.
Prescription drug middlemen fight FTC oversight at Eighth Circuit
November 19, 2025 / FTC lawsuit PBMs / insulin pricing litigation / Express Scripts FTC / drug cost regulation / antitrust pharmacy middlemen
Major pharmacy benefit managers, including Express Scripts, are challenging the constitutionality of FTC administrative proceedings in the Eighth Circuit, arguing the agency’s internal process undermines due process and inflates drug prices—especially for insulin—through alleged anticompetitive practices.
FDA Pilots Faster Clarifications to Meeting Minutes
November 19, 2025 / FDA / drug development / meeting clarification / regulatory communication / sponsor guidance
The FDA launched a pilot program allowing drug sponsors to request rapid clarifications of meeting minutes, aiming to cut delays in drug development by offering targeted, single-discipline responses within three business days via email.
UnitedHealth adds former FDA commissioner Scott Gottlieb to board
November 19, 2025 / UnitedHealth / Scott Gottlieb / FDA / healthcare regulation / board appointment
UnitedHealth has appointed former FDA Commissioner Scott Gottlieb, M.D., to its board of directors, signaling a strategic move to strengthen its regulatory engagement amid increasing federal oversight of healthcare payers and pharmacy benefit managers.
Pfizer in $41.5 million settlement with Texas over ADHD drug for children
November 19, 2025 / Pfizer / ADHD medication / Medicaid / Quillivant XR / drug settlement / Texas
Pfizer and Tris Pharma agreed to a $41.5M settlement with Texas over allegations they manipulated testing data for Quillivant XR, an ADHD drug for children, leading to ineffective dosing and defrauding the state’s Medicaid program.
// Research & Development
Focused ultrasound can be safely used in children being treated for brain cancer
November 19, 2025 / focused ultrasound / brain cancer / pediatrics / blood-brain barrier / glioma treatment / children
Columbia researchers demonstrated that focused ultrasound can safely open the blood-brain barrier in children with brain cancer, enabling effective chemotherapy delivery. This non-invasive method offers promise for improving treatment outcomes in aggressive pediatric brain tumors like diffuse midline glioma.
Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease
November 19, 2025 / mitapivat / sickle cell / RISE UP / hemoglobin response / pyruvate kinase / Agios
Agios’ Phase 3 RISE UP trial showed mitapivat significantly improved hemoglobin levels and markers of hemolysis in sickle cell disease patients. While it reduced pain crises, statistical significance was not met. Subgroup analysis revealed additional clinical benefits.
Fast Track Designation for Dewpoint’s gastric cancer candidate
November 19, 2025 / gastric cancer / β-catenin / Fast Track / condensate modulator / Dewpoint Therapeutics / DPTX3186
The FDA granted Fast Track designation to Dewpoint’s DPTX3186, a first-in-class oral condensate modulator targeting β-catenin for gastric cancer. This status supports accelerated development of the novel therapy, now entering Phase Ia/IIa clinical trials in the U.S.
Common gout drug may reduce risk of heart attack and stroke
November 14, 2025 / colchicine / cardiovascular disease / heart attack / stroke prevention / anti-inflammatory drug / gout treatment
A Cochrane review of 12 trials found low-dose colchicine significantly reduces heart attack and stroke risk in patients with cardiovascular disease, without increasing serious side effects. Mild gastrointestinal symptoms were noted, supporting colchicine’s potential in secondary prevention.
Eledon’s transplant rejection drug shows promise in Phase I/II diabetes trial
November 19, 2025 / islet transplantation / type 1 diabetes / insulin independence
tegoprubart / transplant rejection / HbA1c control
Eledon’s immunotherapy drug tegoprubart enabled insulin independence in type 1 diabetes patients following islet transplantation, showing sustained HbA1c control without calcineurin inhibitors in a Phase I/II trial, marking a significant advance in transplant rejection prevention.
// Politics
EuropaBio calls for “bold approach to investment” amid EU Biotech Act
November 13, 2025 / EU Biotech Act / biotech investment / regulatory reform / EuropaBio / lab-to-market / biotech innovation
EuropaBio urges the EU to adopt bold investment strategies in the upcoming Biotech Act to bridge the gap between research and commercialization, focusing on regulatory reform, startup financing, workforce development, and AI integration in biotechnology.
Michigan House committee hears testimony on Chinese influence in education, biotech, manufacturing
November 17, 2025 / China biotech / genetic data / biosecurity / BGI testing / U.S. security / genomics
Testimony before the Michigan House highlighted national‑security concerns over U.S. dependence on Chinese biotechnology, including fears that companies like BGI could access Americans’ genetic data through diagnostic testing, raising potential risks for data privacy and biosecurity.
Trump’s broadside against health insurers is a cautionary tale for industry
November 16, 2025 / Trump healthcare / insurance subsidies / drug pricing / ACA funding / pharma deals
Trump’s recent criticism of health insurers and praise for drugmakers highlights a strategic divide: insurers face uncertainty over expiring ACA subsidies, while pharmaceutical firms are securing favorable deals by cooperating on pricing to avoid steep proposed tariffs.
Amid Rising Costs For Seniors, U.S. Senator Kirsten Gillibrand, Democrat Colleagues ‘Demand’ President Trump Release Next Round Of Medicare-Negotiated Drug Prices
November 19, 2025 / Medicare / drug prices / seniors / Gillibrand / Trump / pharma
Senator Kirsten Gillibrand urges President Trump to release 2027 Medicare-negotiated drug prices, criticizing his administration for prioritizing pharmaceutical industry interests over seniors struggling with rising medication and living costs, despite legislative efforts to reduce drug prices through Medicare negotiations.
RFK Jr. calls for unity after supporters attack Trump aides
November 14, 2025 / RFK Jr. / vaccine policy / HHS / health freedom / MAHA movement / chronic disease
Health Secretary RFK Jr. defended Trump aides amid internal conflict over his public health agenda, including vaccine policy and chronic disease reform, as critics accused staff of obstructing his movement to reduce pharmaceutical influence and promote “health freedom.”